Reference
Wang A, et al. Inetetamab in combination with rapamycin and chemotherapy for trastuzumab-treated metastatic human epidermal growth factor receptor 2-positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway. Cancer Reports 6 : 1-8, No. 9, Sep 2023. Available from: URL: https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.1864
Rights and permissions
About this article
Cite this article
Antineoplastics. Reactions Weekly 1979, 46 (2023). https://doi.org/10.1007/s40278-023-47773-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-47773-6